Description: Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Home Page: www.mereobiopharma.com
0A9G Technical Analysis
One Cavendish Place
London,
W1G 0QF
United Kingdom
Phone:
44 33 3023 7300
Officers
| Name | Title |
|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, CEO & Executive Director |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary |
| Ms. Christine Fox CPA | Chief Financial Officer |
| Dr. John P. Richard M.B.A. | Co-Founder & Chief Business Officer |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer |
| Dr. Jackie Parkin | Senior VP & Therapeutic Head |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development |
| Mr. Bo Kara | Senior VP and Head of Pharmaceutical Development & CMC |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |